Abstract
Hopes for correcting the instruction tape in patients with genetic disease are being intensively explored. Initial efforts centered on monogenic immunodeficiency states, but in a pattern not wholly expected by researchers, the “acquired genetic diseases” of cancer and AIDS account for most ongoing clinical trials. Experience with adenosine deaminase deficiency shows the difficulties encountered in creating practical gene therapies.